Dendreon Corp. (DNDN), the maker of prostate-cancer drug Provenge, filed for Chapter 11 bankruptcy protection on Monday and said it has reached agreements on the terms of a financial restructuring with investors holding about 84% of the company’s $620 million of convertible notes. The Seattle-based drugmaker also said the restructuring may involve a recapitalization, or […] View the full post at: Drugmaker Dendreon (DNDN) Files for Bankruptcy Protection Related posts: GM Weeks from Bankruptcy Filing Bankruptcy Reform: A Necessary Component of Economic Recovery The Treasury Dept. Preparing for a Chrysler Bankruptcy Filing